RxDoctor Payments DataLook up a doctor →

Sumati Gupta, MD

Geriatric Medicine · Salt Lake City, UTNPI 1003906603

Payments from drug & device makers

$1,927,388in general payments, 2019–2025

Across 319 payments — averaging $6041.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$699K
  • AstraZeneca$475K
  • Seagen Inc.$216K
  • Novartis$214K
  • Incyte Corporation$183K
  • Clovis Oncology, Inc.$74K
  • plus $68K from 6 others
$4,038in research payments, 2019–2025

Across 8 payments — averaging $504.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Astellas Pharma Global Development$4K

What the payments were for

  • Speaking & faculty fees$72477%
  • Food & beverage$334%
  • Education$18420%

General payments by program year

19
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few geriatric medicine providers in Utahto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$36,947
Medicare patients
78
Services billed
511

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
WeliregBelzutifan28$666,408
InlytaAxitinib11$230,519
XtandiEnzalutamide24$157,932
OrgovyxRelugolix26$65,591
EliquisApixaban18$21,175
Abiraterone Acetate29$18,599
Prochlorperazine Maleate25$417
Prednisone52$269
Levothyroxine Sodium25$230
Potassium Chloride12$128
Ondansetron Hcl15$122
Amlodipine Besylate18$118
Omeprazole14$85
Olanzapine13$83
Famotidine12$81

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckWelireg$59,956$666,40828 claims
PfizerInlyta, Eliquis$698,694$251,69329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few geriatric medicine providers in Utahon file to place this against a meaningful peer group, so we don't.

Other geriatric medicine in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →